✦ LIBER ✦

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

✍ Scribed by Jacobson, Ira M.; Gordon, Stuart C.; Kowdley, Kris V.; Yoshida, Eric M.; Rodriguez-Torres, Maribel; Sulkowski, Mark S.; Shiffman, Mitchell L.; Lawitz, Eric; Everson, Gregory; Bennett, Michael; Schiff, Eugene; Al-Assi, M. Tarek; Subramanian, G. Mani; An, Di; Lin, Ming; McNally, John; Brainard, Diana; Symonds, William T.; McHutchison, John G.; Patel, Keyur; Feld, Jordan; Pianko, Stephen; Nelson, David R.

Book ID: 120326813
Publisher: Massachusetts Medical Society
Year: 2013
Tongue: English
Weight: 479 KB
Volume: 368
Category: Article
ISSN: 0096-6762
DOI: 10.1056/NEJMoa1214854

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sofosbuvir and Ribavirin for Hepatitis C

Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics

✍ Osinusi, Anuoluwapo; Meissner, Eric G.; Lee, Yu-Jin; Bon, Dimitra; Heytens, Laur 📂 Article 📅 2013 🏛 American Medical Association 🌐 English ⚖ 294 KB

Chronic hepatitis C genotype 2 or 3 shor

Chronic hepatitis C genotype 2 or 3 short treatment

✍ Ricardo Moreno-Otero; María Trapero; José A. Moreno-Monteagudo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

Dalgard et al. 1 reported interesting data on 14 versus 24 weeks of combination therapy in patients with hepatitis C virus (HCV) genotype 2 or 3, and they concluded that it is rational to treat those patients with rapid virological response (RVR) for only 14 weeks. Adequate treatment duration is gen

Sofosbuvir–Based Antiviral Therapy for T

Sofosbuvir–Based Antiviral Therapy for Treatment Naïve Hepatitis C Genotypes 1, 2, and 3

✍ Sharma, Pratima 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Combination of Daclatasvir and Sofosbuvi

Combination of Daclatasvir and Sofosbuvir for Hepatitis C Genotypes 1, 2, and 3

✍ Bari, Khurram; Sharma, Pratima 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 61 KB

A Decision Analytic Markov Model to Eval

A Decision Analytic Markov Model to Evaluate the Health Outcomes of Sofosbuvir for Previously Untreated Patients and Those Without Treatment Options with Chronic Hepatitis C Virus Genotype 2 Infection

✍ Younossi, Z.M.; Gordon, S.; Saab, S.; Ahmed, A.; Cure, S.; Guerra, I. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Individualizing treatment duration in he

Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients

✍ Alessandra Mangia 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 138 KB